成都先导(688222) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for 2023 was 371 million CNY, representing a year-on-year growth of 12.64%[5][6] - The net profit attributable to shareholders was 4,071.85 CNY, with a non-recurring net profit of 345.19 CNY, showing a year-on-year increase of 61.16%[7][8] - Operating cash flow net amount was 125 million CNY, with R&D investment totaling 79.61 million CNY, accounting for 21.44% of revenue[10] - The overall gross margin for the main business was 49.28%, reflecting a year-on-year increase of 137.42%[10][11] - In Q1 2024, the company reported revenue of 107 million CNY, a year-on-year increase of 54.35%[25][24] Research and Development - The R&D investment in Q1 2024 was 12.10% of revenue, amounting to approximately 12.99 million CNY[26] - The company has completed over 50 novel E3 ubiquitin ligases, available for direct customer orders, enhancing its service offerings[41] - The DEL library now contains over 12 trillion molecules, with more than 6,000 scaffold types and nearly 40,000 synthetic building blocks, showcasing its extensive capabilities[37] - The company has multiple drug development projects in various stages, with three projects in Phase I clinical trials: HG030, HG381, and HG146, with HG146's Phase I clinical trial for multiple myeloma officially ending in July 2023[57] - The company has a total of 374 R&D personnel, with 97% holding a bachelor's degree or higher[51] - The company has filed for 296 invention patents and 119 software copyrights in 2023, with 43 patents granted[54] - The company is currently constructing a global drug R&D and production base in Chengdu[49] - Two projects are in the IND application preparation stage: HG153 and HG248[57] - The company has developed an internationally leading DNA-encoded compound library technology platform, focusing on small molecule and nucleic acid drug discovery and optimization[64] - The company has two projects in the preclinical candidate compound (PCC) screening stage: HGP0508 and HGP1069[57] Collaborations and Partnerships - The company has established deep collaborations with several global biopharmaceutical companies and research institutions in 2023, including ARase Therapeutics and Pierre Fabre Laboratories[47] Shareholder Returns - The company distributed a cash dividend of 0.5 yuan per 10 shares in 2023, totaling 19.97 million yuan, and has returned over 110 million yuan to investors through dividends and buybacks since its listing[66] Awards and Recognition - The company has received the "ESG Golden Bull Award" for its technological leadership in the first National Cup by China Securities Journal and Guoxin Consulting[67] Business Development - The DEL platform revenue increased by 49.33% during the reporting period, highlighting its significance in the company's business development[28] - The FBDD/SBDD platform saw a revenue increase of 78.83% due to project milestone income and favorable exchange rate changes[28]